Patients on allergen immunotherapy should be evaluated at least every 6-12 months while receiving immunotherapy:

- to assess efficacy
- to implement and reinforce its safe administration and to monitor adverse reactions
- to assess patient’s compliance with treatment
- to determine whether immunotherapy can be discontinued
- to determine whether adjustments in immunotherapy dosing schedule or allergen content are necessary.

A decision about continuation of effective immunotherapy should generally be made after the initial period of up to 5 years of treatment. The severity of disease, benefits sustained from treatment, and the convenience of treatment are all factors that should be considered in determining whether to continue or stop immunotherapy for any individual patient.

Evidence of significant benefit from immunotherapy. _____

Evidence of compliance with current immunotherapy program. _____

Discuss evidence for benefit and compliance:

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Informed consent for continuation over 5 years.

At least one of the following is required for long-term IT. _____

History of failure of previous discontinuation of immunotherapy after at least 3 year course. _____

Continued need for Hymenoptera hypersensitivity prophylaxis;

Risk-benefit assessment favors continued immunotherapy. _____

Other extenuating medical circumstance as described below.

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Physician signature_________________________________________________  Date_______________________________

Updated 10-10-07